Handelsinvest Investeringsforvaltning Sells 143 Shares of argenx SE (NASDAQ:ARGX)

Handelsinvest Investeringsforvaltning lessened its position in argenx SE (NASDAQ:ARGX) by 20.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 555 shares of the company’s stock after selling 143 shares during the period. Handelsinvest Investeringsforvaltning’s holdings in argenx were worth $219,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of argenx by 420.0% in the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after buying an additional 63 shares in the last quarter. FNY Investment Advisers LLC bought a new position in argenx during the fourth quarter valued at approximately $38,000. Mather Group LLC. bought a new position in argenx during the first quarter valued at approximately $38,000. Benjamin F. Edwards & Company Inc. bought a new position in argenx during the fourth quarter valued at approximately $60,000. Finally, Principal Securities Inc. bought a new position in argenx during the fourth quarter valued at approximately $99,000. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on ARGX shares. Wells Fargo & Company increased their price objective on shares of argenx from $478.00 to $542.00 and gave the company an “overweight” rating in a research report on Monday, June 24th. Wedbush restated an “outperform” rating and set a $519.00 price objective on shares of argenx in a research report on Wednesday, June 26th. Morgan Stanley lowered their price objective on shares of argenx from $515.00 to $510.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 28th. JPMorgan Chase & Co. decreased their price target on shares of argenx from $560.00 to $500.00 and set an “overweight” rating on the stock in a research report on Monday, May 13th. Finally, Truist Financial increased their price target on shares of argenx from $440.00 to $480.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average price target of $525.42.

argenx Stock Performance

ARGX opened at $435.29 on Thursday. The stock has a market capitalization of $25.87 billion, a price-to-earnings ratio of -76.91 and a beta of 0.64. The company has a fifty day moving average of $386.70 and a 200 day moving average of $386.09. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $550.76.

argenx (NASDAQ:ARGX) last posted its earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The company had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same period in the previous year, the business posted ($0.52) earnings per share. On average, equities research analysts forecast that argenx SE will post -2.88 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.